Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,510 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discovery of a potent and selective Axl inhibitor in preclinical model.
Inoue S, Yamane Y, Tsukamoto S, Azuma H, Nagao S, Murai N, Nishibata K, Fukushima S, Ichikawa K, Nakagawa T, Hata Sugi N, Ito D, Kato Y, Goto A, Kakiuchi D, Ueno T, Matsui J, Matsushima T. Inoue S, et al. Among authors: ichikawa k. Bioorg Med Chem. 2021 Jun 1;39:116137. doi: 10.1016/j.bmc.2021.116137. Epub 2021 Apr 21. Bioorg Med Chem. 2021. PMID: 33930844
Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine derivatives as novel selective Axl inhibitors.
Inoue S, Yamane Y, Tsukamoto S, Murai N, Azuma H, Nagao S, Nishibata K, Fukushima S, Ichikawa K, Nakagawa T, Hata Sugi N, Ito D, Kato Y, Goto A, Kakiuchi D, Ueno T, Matsui J, Matsushima T. Inoue S, et al. Among authors: ichikawa k. Bioorg Med Chem Lett. 2021 Sep 15;48:128247. doi: 10.1016/j.bmcl.2021.128247. Epub 2021 Jul 13. Bioorg Med Chem Lett. 2021. PMID: 34271070
Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies.
Adachi Y, Kamiyama H, Ichikawa K, Fukushima S, Ozawa Y, Yamaguchi S, Goda S, Kimura T, Kodama K, Matsuki M, Miyano SW, Yokoi A, Kato Y, Funahashi Y. Adachi Y, et al. Among authors: ichikawa k. Cancer Res. 2022 Jan 15;82(2):292-306. doi: 10.1158/0008-5472.CAN-20-2426. Epub 2021 Nov 9. Cancer Res. 2022. PMID: 34753772 Free PMC article.
ER-851, a Novel Selective Inhibitor of AXL, Overcomes Resistance to Antimitotic Drugs.
Tsukamoto S, Sugi NH, Nishibata K, Nakazawa Y, Ito D, Fukushima S, Nakagawa T, Ichikawa K, Kato Y, Kakiuchi D, Goto A, Itoh-Yagi M, Aota T, Inoue S, Yamane Y, Murai N, Azuma H, Nagao S, Sasai K, Akagi T, Imai T, Matsui J, Matsushima T. Tsukamoto S, et al. Among authors: ichikawa k. Mol Cancer Ther. 2023 Jan 3;22(1):12-24. doi: 10.1158/1535-7163.MCT-21-0879. Mol Cancer Ther. 2023. PMID: 36279567
"Anti-inflammatory Therapies in Atherosclerosis - Where are we going?".
Punnanithinont N, Kambalapalli S, Iskander B, Ichikawa K, Krishnan S, Lakshmanan S, Roy SK, Budoff M. Punnanithinont N, et al. Among authors: ichikawa k. Curr Atheroscler Rep. 2024 Dec 19;27(1):19. doi: 10.1007/s11883-024-01267-7. Curr Atheroscler Rep. 2024. PMID: 39699771 Review.
CGC1, a new reference genome for Caenorhabditis elegans.
Ichikawa K, Shoura MJ, Artiles KL, Jeong DE, Owa C, Kobayashi H, Suzuki Y, Kanamori M, Toyoshima Y, Iino Y, Rougvie AE, Wahba L, Fire AZ, Schwarz EM, Morishita S. Ichikawa K, et al. bioRxiv [Preprint]. 2024 Dec 6:2024.12.04.626850. doi: 10.1101/2024.12.04.626850. bioRxiv. 2024. PMID: 39677790 Free PMC article. Preprint.
1,510 results